Skip to main content
Clinical Trials/NCT07762326
NCT07762326Not yet recruitingNot Applicable

Effect of Artificial Intelligence Based Cognitive Training on Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis

Cairo University0 sites40 target enrollmentStarted: August 20, 2026Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
40
Primary Endpoint
sleep disability

Study Overview

Brief Summary

this study will be conducted to investigate the effect of artificial intelligence (AI) based cognitive training on sleep disorders and quality of life in patients with multiple sclerosis.

Detailed Description

Multiple sclerosis (MS) is a chronic progressive inflammatory autoimmune neurodegenerative disease of central nervous system (CNS) and it is considered to be the most prevalent neurological disability of young adults, often leads to severe physical or cognitive incapacitation. The severity of disability in MS patients is increased not only by motor disorders and other neurological deficit, but by the presence of cognitive impairment (CI), psycho-emotional disorders, like anxiety and/or depression, and sleep disorders (SD). Cognitive dysfunction is one of the most common and consequential symptoms of MS. Impairments in processing speed, working memory, learning, executive function, visuospatial processing, and language function affect an estimated 42% to70% of individuals with MS, and constitute a major cause of loss of employment and reduced quality of life. Despite its high prevalence and effect, there are no definitive treatments for cognitive dysfunction in MS, and the identification of appropriate strategies to improve cognition in MS is hindered by a poor understanding of modifiable factors that may influence its severity. AI is playing a significant role in harnessing neuroplasticity for cognitive enhancement through innovative applications such as cognitive training programs.These programs, driven by machine learning algorithms, can adapt to individual user performance, providing personalized training that optimizes cognitive functions such as memory, attention, and problem-solving .

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Masking Description

opaque sealed envelope

Eligibility Criteria

Ages
25 Years to 40 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patient's age ranges from 25-40 years.
  • •Patient with EDSS not more than
  • •Patients who have no relapses for the previous three months.
  • •Patients with sufficient cognitive abilities that enables them to understand and follow
  • •instructions with a score more than 24 according to the Mini-Mental State Examination scale

Exclusion Criteria

  • •Mechanical or neuromascular problems.
  • •Cardiovascular problems (unstable angina, recent myocardial infarction within the last three months, congestive heart failure, significant heart valve dysfunction, or unstable hypertension) or pulmonary disorders.
  • •Auditory problems.
  • •Sensory impairment caused by other diseases except the MS such as diabetes mellitus.

Arms & Interventions

cognitive Therapy by artificial intillegence

Experimental

Twenty patients with multiple sclerosis will receive a cognitive therapy by Lumosity application in addition to a designed physical-therapy program 3 times per week for 8 weeks

Intervention: designed physical-therapy program (Other)

cognitive Therapy by artificial intillegence

Experimental

Twenty patients with multiple sclerosis will receive a cognitive therapy by Lumosity application in addition to a designed physical-therapy program 3 times per week for 8 weeks

Intervention: cognitive Therapy by artificial intillegence (Other)

designed physical-therapy program

Active Comparator

Twenty patients with multiple sclerosis will receive a designed physical-therapy program 3 times per week for 8 weeks)

Intervention: designed physical-therapy program (Other)

Outcomes

Primary Outcomes

sleep disability

Time Frame: up to eight weeks

Pittsburgh Sleep Quality Index will be used to assess sleep disability. it gives impression on sleep quality, sleep latency, sleep duration, usual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction over one month, The sum of scores for these seven components yields one global score. Scoring of the answers is based on a 0 to 3 scale and a global sum equal or larger than 5 indicates a "poor" sleeper

daytime sleepiness

Time Frame: up to eight weeks

Epworth Sleepiness Scale will be used to assess daytime sleepiness. It measures the general level of daytime sleepiness it is composed of 8 items to rate on a 4 -point scale (0-3). A higher score indicates higher level of daytime sleepiness. Using a cut-off score \> 10, it is possible to identify individuals with excessive daytime sleepiness. Scores \>16 indicates ever sleepiness

Secondary Outcomes

  • cognitive disability(up to eight weeks)
  • oxygen saturation(up to eight weeks)
  • heart rate(up to eight weeks)
  • life disability(up to eight weeks)
  • fatigue severity(up to eight weeks)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Rania Hamed Rashad Ahmed

principle investigator : rania hamed rashad ahmed

Cairo University

Similar Trials